Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups

Zhenghui Li1, Ashlesh Krishna Murthy1, Li Hao1

  • 1Pfizer Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.

PubMed

Insights

Factor H binding protein (FHbp) is a key virulence factor in invasive meningococcal disease (IMD). FHbp-based vaccines show potential for broad protection against IMD, including MenB disease.

Area of Science:

  • Microbiology
  • Vaccinology
  • Epidemiology

Background:

  • Invasive meningococcal disease (IMD) is caused by *Neisseria meningitidis* serogroups A, B, C, W, X, and Y.
  • Factor H binding protein (FHbp) is a critical meningococcal virulence factor and an antigen in licensed serogroup B (MenB) vaccines.

Purpose of the Study:

  • To review the biology and epidemiology of FHbp.
  • To assess the protective potential of FHbp vaccine antigens against IMD.

Main Methods:

  • Literature review and analysis of the PubMLST database.
  • Examination of MenB genotypes, multilocus sequence typing (MLST)/clonal complexes, FHbp subfamilies, and FHbp/PorA variants.

Main Results:

  • FHbp subfamily distribution and variant types show stable genotypes, distribution, and diversity over time.
  • Analyses included prevalent MLST/clonal complexes and FHbp/PorA variants.

Conclusions:

  • The stability of FHbp variant types supports the potential of FHbp-containing protein-based vaccines for IMD protection.
  • MenB-FHbp (Trumenba®) utilizes FHbp antigens from subfamilies A and B for protection.